

12/28/99

JCS25 U.S. PTO

12-29-99 A

JCS25 U.S. PTO
09/473830JCS25 U.S. PTO
12/28/99U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**UTILITY PATENT APPLICATION
TRANSMITTAL LETTER
UNDER RULE 37 C.F.R. 1.53(b)**ATTORNEY DOCKET NO.:
2844/53802

Address to:
 Assistant Commissioner for Patents
 Washington, D.C. 20231
 Box Patent Application

Transmitted herewith for filing is the patent application of

Inventor(s)

Jeffrey M. LEIDEN
 Eric SVENSSON

For : EFFICIENT AND STABLE IN VIVO GENE TRANSFER TO
 CARDIOMYOCYTES USING RECOMBINANT ADENO-ASSOCIATED VIRUS
 VECTORS

1. 11 sheets of specification, 2 sheets of claims and 1 sheet of abstract.
2. 2 sheet of drawings.
3. Return Receipt Postcard.
4. Related Application:

The present application claims the benefit, under 35 U.S.C. § 119(e) of U.S.
 Provisional Application No. 60/113,923, filed December 28, 1998.

5. The filing fee has been calculated as shown below:

	NUMBER FILED	NUMBER EXTRA*	RATE (\$)	FEE (\$)
BASIC FEE				760.00
TOTAL CLAIMS	27 - 20 =	7	18.00	126.00
INDEPENDENT CLAIMS	1 - 3 =	0	78.00	0.00
MULTIPLE DEPENDENT CLAIM PRESENT			260.00	260.00
*Number extra must be zero or larger			TOTAL	1,146.00
If applicant is a small entity under 37 C.F.R. §§ 1.9 and 1.27, then divide total fee by 2, and enter amount here.			SMALL ENTITY TOTAL	0.00

6. Please charge the required application filing fee of **\$1,146.00 (large entity)**, and any other fees that may be required, to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**. A duplicate of this sheet is enclosed.
7. The Commissioner is hereby authorized to charge payment of the following fees, associated with this communication or arising during the pendency of this application, or credit any overpayment to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**:
 - A. Any additional filing fees required under 37 C.F.R. § 1.16;
 - B. Any additional patent application processing fees under 37 C.F.R. § 1.17;
 - C. Any additional patent issue fees under 37 C.F.R. § 1.18;
 - D. Any additional document supply fees under 37 C.F.R. § 1.19;
 - E. Any additional post-patent processing fees under 37 C.F.R. § 1.20; or
 - F. Any additional miscellaneous fees under 37 C.F.R. § 1.21.

Respectfully submitted,

M. Lisa Wilson

Dated: 12/28/99

By: Mary e. weiss Reg No 30,333
M. Lisa Wilson (Reg. No. 34,045)

KENYON & KENYON
One Broadway
New York, New York 10004
Telephone: (212) 425-7200
Facsimile: (212) 425-5288

EFFICIENT AND STABLE *IN VIVO* GENE TRANSFER TO CARDIOMYOCYTES
USING RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS

5 This application is a continuation-in-part application of provisional application
U.S. Ser. No. 60/113,923, filed December 28, 1998, which is incorporated by reference
herein in its entirety.

This work was supported in part by grants from the National Institutes of Health
(DK-48997, AR-42895, and HL-54592) to Jeffrey M. Leiden.

10 FIELD OF THE INVENTION

The ability to stably and efficiently program recombinant gene expression in
cardiomyocytes facilitates gene therapy approaches for a variety of cardiovascular
diseases and conditions. Accordingly, this invention relates to the use of recombinant
15 adeno-associated virus (rAAV) vectors to transduce cardiomyocytes *in vivo* by infusing
the rAAV into a coronary artery or coronary sinus. For example, coronary artery
perfusion of mouse hearts with a rAAV encoding the LacZ gene produced efficient
transduction of cardiomyocytes which was stable for at least 8 weeks. Moreover, rAAV
infection is not associated with detectable myocardial inflammation or myocyte necrosis.
Thus, rAAV is a useful vector for the stable expression of therapeutic genes in the
20 myocardium and can be used to deliver genes for inducing angiogenesis, inhibiting
angiogenesis, stimulating cell proliferation, inhibiting cell proliferation and/or treating or
ameliorating other cardiovascular conditions.

BACKGROUND OF THE INVENTION

25 Myocardial gene therapy can be used for the treatment of a number of
cardiovascular diseases, including ischemic cardiomyopathies, congestive heart failure,
and malignant arrhythmias (Nabel (1995) *Circulation* 91:541-548). A useful vector for
myocardial gene delivery will allow efficient and stable transduction of cardiomyocytes
with a variety of transgenes after either direct intramyocardial injection or infusion into
30 the coronary arteries or sinuses. For example, plasmid DNA vectors injected directly into
the left ventricular myocardium have been expressed for ≥6 months by cardiomyocytes

adjacent to the area of injection (Lin et al. (1990a) *Circulation* 82:2217-2221; Kass et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:11498-11502; and Guzman et al. (1993) *Circ. Res.* 73:1202-1207). However, the therapeutic usefulness of this approach has been limited by the low efficiency of cardiomyocyte transduction (0.1% to 1.0% of cardiomyocytes in the area of injection).

Both intramyocardial injection and intracoronary infusion of replication-defective adenovirus (RDAd) vectors have been used to efficiently transduce cardiomyocytes in rodents, rabbits, and pigs *in vivo*. However, the feasibility of adenovirus-mediated gene transfer has been limited by immune responses to viral and foreign transgene proteins, which cause significant myocardial inflammation, eliminate virus-transduced cells within 30 days of infection, and thereby result in transient recombinant gene expression in immunocompetent hosts (Guzman et al. (1993) *Circ. Res.* 73:1202-1207; French et al.(1994) *Circulation* 90:2414-2424; and Barr et al.(1994) *Gene Ther.* 1:51-58).

Recently, rAAV vectors have been shown to program efficient and stable recombinant gene expression in skeletal muscle and liver in both rodents and primates (Fisher et al.(1997) *Nat. Med.* 3:306-312; Kessler et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:14082-14087; and Snyder et al. (1997) *Nat. Genet.* 16: 270-276) and in cardiac muscle directly injected with rAAV (U.S. Patent No. 5,858,351 to Podsakoff et al.). However, since rAAV vectors used in gene therapy applications, unlike RDAd, do not encode viral proteins, the rAAV vectors have not been associated with immune responses to foreign transgene proteins.

While a previous report showed that rAAV can transduce cardiomyocytes *in vivo*, the efficiency of rAAV-mediated transgene expression in the heart was both low (about 0.2%) and localized (Kaplitt et al. (1996) *Ann. Thorac. Surg.* 62:1669-1676). In that study, pigs hearts were rapidly perfused with a low titer of rAAV (less than 10^4 expressing units AAV per gram of body weight). Based on those results, infusing rAAV into the heart would have severely limited use as a vector for myocardial gene therapy. However, as demonstrated herein, this invention establishes that by infusing rAAV in much higher amounts proportional to body weight of the animal and for particular time periods, then rAAV provides unexpected efficient and stable gene transfer into the heart, opening up use of rAAV vectors to deliver therapeutically-effective molecules to

cardiomyocytes in amounts useful for treating or ameliorating cardiac diseases or conditions.

SUMMARY OF THE INVENTION

The present invention is directed to a method of treating a cardiovascular condition by infusing an rAAV vector into a coronary artery or a coronary sinus for a time and in an amount sufficient to stably and efficiently transduce the cardiomyocytes perfused by the artery or sinus. The rAAV vector encodes at least one nucleic acid which is operably linked to a control region and which encodes a therapeutically-effective molecule. After infusion and transduction of the cardiomyocytes, the therapeutically-effective molecule is expressed in an amount effective to treat or ameliorate the cardiovascular condition.

Thus, this method provides a means of delivering AAV vectors in a stable and efficient manner. The vector can be infused by any convenient means and in conjunction with surgery or other cardiac procedure, if desired.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Schematic of AAV_{CMV-LacZ}. ITR indicates inverted terminal repeats; BGH pA, bovine growth hormone polyadenylation signal; CMV Pr, CMV immediate-early promoter; LacZ, bacterial *LacZ* gene.

Figure 2. Gene transfer into cardiomyocytes *in vivo* with AAV_{CMV-LacZ}. Gross sections (left) and photomicrographs (right) of mouse hearts after coronary artery perfusion with 1.5 x 10⁹ IU of AAV_{CMV-LacZ} and staining with X-gal. Bar=25 microns.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to treating cardiovascular conditions using rAAV vectors. In accordance with the invention, an rAAV vector encoding a therapeutically effective molecule is infused into a coronary artery or a coronary sinus to deliver the vector to the heart in a manner which stably and efficiently transduces cardiomyocytes. It has unexpectedly been found that the ability to obtain stable and efficient transduction of

cardiomyocytes by rAAV depends upon the duration of the infusion period and the amount of virus infused relative to body weight.

Moreover, rAAV displays significant advantages for myocardial gene transfer compared with plasmid DNA or adenovirus vectors. For example, rAAV, when delivered as described herein, allows efficient transduction of cardiomyocytes. Further, rAAV vectors program stable expression of foreign transgenes in immunocompetent hosts. The stability of transgene expression observed with rAAV even after expression of a foreign transgene protein likely reflects the fact that rAAV vectors, unlike their adenovirus counterparts, do not express any viral gene products and are therefore significantly less immunogenic. This lack of immunogenicity represents a major advantage of rAAV for myocardial gene transfer.

Hence, the invention is directed to a method of treating a cardiovascular condition which comprises infusing an rAAV vector into a coronary artery or sinus of an animal for a time and in an amount sufficient to stably and efficiently transduce cardiomyocytes perfused by the artery or sinus, wherein that vector encodes at least one nucleic acid, *i.e.*, the transgene, encoding a therapeutically-effective molecule; and expressing the therapeutically-effective molecule in an amount effective to treat or ameliorate the cardiovascular condition. Further, the nucleic acid is operably linked to a control region, *e.g.*, promoters, enhancers, termination signals and the like, to permit expression of the molecule. When more than one nucleic acid is present on the rAAV vector, each can be controlled separately by individual control regions or, any group of them, or all of them, can be controlled in an operon, *i.e.*, with one control region driving expression of multiple genes on a single transcript.

rAAV vectors useful in the present invention can be any rAAV vector with one or more transgenes (or nucleic acids of interest) inserted therein in a manner allowing expression of the transgene under control of appropriate regulatory elements such as promoters, enhancers, transcription terminators and the like. rAAV vectors are well known in the art and can be prepared by standard methodology known to those of ordinary skill in the art. For example, U.S. Patent No. 5,858,351 and the references cited therein describe a variety of rAAV vectors suitable for use in gene therapy as well as how to make and propagate those vectors (*see, e.g.*, Kotin (1994) Human Gene Therapy

5:793-801 or Berns, "Parvoviridae and their Replication" in Fundamental Virology, 2nd Edition, (Fields & Knipe, eds.)).

A "transgene" or "nucleic acid of interest" or the "nucleic acid encoded in the rAAV vector" as used herein refers to any nucleotide sequence which encodes a therapeutically-effective molecule that can be used to treat a cardiovascular condition. Such transgenes may normally be foreign to the animal being treated or may be a gene normally found in that animal for which altered expression (e.g., temporal, spatial or amount of expression) is desired to achieve a particular therapeutic effect. The therapeutically-effective molecule encoded by the transgene is protein or an anti-sense RNA that imparts a benefit to the animal or subject undergoing treatment or amelioration of a cardiac condition or disease in accordance with this invention.

10 Proteins that can be administered to treat or ameliorate cardiovascular conditions are numerous and include, but are not limited to, molecules competent to induce angiogenesis, e.g., angiogenesis factors; anti-angiogenesis factors; proteins capable of inhibiting vascular smooth muscle cell proliferation; proteins useful for treating atherosclerosis; proteins useful for treating restenosis, proteins useful for stimulating cardiomyocyte activity; proteins capable of secretion from cardiomyocytes that exert their effect in the heart or capable of transport to other locales for treatment of a cardiovascular condition or disease; hormones, cytokines or growth factors useful for treating cardiac conditions or diseases; and proteins capable of stimulating vascular smooth muscle cell proliferation. Other genes encoding proteins useful in this invention include ion channel genes, contractile protein genes, phospholamban encoding genes and genes encoding β adrenergic receptors or β adrenergic kinases.

15 Angiogenic factors include, but are not limited to FGF-1, FGF-2, FGF-5, VEGF, HIF-1 and the like. Proteins useful for treating restenosis include thymidine kinase, cytosine deaminase, p21, p27, p53, Rb, and NF- κ B. Hence, this invention can be used to deliver any protein via an rAAV vector that has a therapeutic benefit for treating or ameliorating a cardiovascular condition or disease.

20 A protein competent to induce angiogenesis or an "angiogenesis factor" as used herein is a protein or substance that causes proliferation of new blood vessels and includes fibroblast growth factors, endothelial cell growth factors or other proteins with such

biological activity. Particular proteins known to induce angiogenesis are FGF-1, FGF-2, FGF-5, VEGF and active fragment thereof, and HIF-1. Proteins competent to inhibit angiogenesis or “anti-angiogenesis factors” are proteins or substances that inhibit the formation of new blood vessels.

5 Anti-sense RNA that can be administered to treat or ameliorate cardiovascular conditions have one of the same activities as proteins useful in the invention. Such RNA include, but are not limited to, c-myb, c-myc and others. Anti-sense RNA molecules, including how to design and use such molecules in expression vectors are well know in the art and can be contructed by routine methodology. Thus a strand of RNA whose sequence of bases is complementary to the sense, or translated, RNA strand can form a duplex to block translation or degradation of a particular mRNA or otherwise control or alter expression of the desired mRNA.

10 As used herein, a “control region” or “regulatory element” refers to polyadenylation signals, upstream regulatory domains, promoters, enhancers, transcription termination sequences and the like which regulate the transcription and translation of a nucleic acid sequence.

15 The term “operably linked” refers to an arrangement of elements wherein the components are arranged so as to perform their usual function. Thus, control regions or regulatory elements operably linked to a coding sequence are capable of effecting the expression of the coding sequence. The control elements need not be contiguous with the coding sequence, so long as they function to direct the expression thereof. Thus, for example, intervening untranslated yet transcribed sequences can be present between a promoter sequence and the coding sequence and the promoter sequence can still be considered “operably linked” to the coding sequence.

20 25 The regulatory elements of the invention can be derived from any source, e.g., viruses, mammals, insects or even synthetic, provided that they function in cardiomyocytes. For example, any promoter can used to control expression of the transgene. Such promoters can be promiscous, i.e., active in many cell types, such as the SV40 early promoter, the mouse mammary tumor virus LTR promoter, the adenovirus major late promoter (Ad MLP), a herpes simplex promoter, a CMV promoter such as the

CMV immediate early promoter, a rous sarcoma virus (RSV) promoter. Alternatively the promoter can be tissue-specific for expression in cardiomyocytes.

The rAAV is delivered to cardiac myocytes by infusion into a coronary artery or coronary sinus. This mode of delivery has also been referred to as intraluminal delivery through a coronary artery, intracoronary delivery or intraarterial delivery. As used herein, infusion into a coronary artery includes intracoronary perfusion. In accordance with the invention, the rAAV vector can be infused when the heart is in situ, i.e., in the body cavity or when the heart or heart tissue (cardiac tissue) has been removed from the body as might occur when the heart is being donated for transplant into a recipient. In the case of a heart being prepared for transplantation or for heart tissue, the vector can be infused through any artery or vein attached thereto, by contacting with or soaking the heart in an appropriately concentrated solution of the vector, or by a combination of both. Thus as described herein, infusion includes delivering rAAV to a heart or heart tissue ex vivo by the means disclosed herein. If necessary, the infusion can be repeated at intervals such as 3 months, 6 months, one year, or as appropriately determined.

As used herein, treating cardiac conditions include treating cardiac or cardiovascular diseases. Examples of cardiac conditions subject to treatment or amelioration according to the method of the present invention include, but are not limited to, myocardial ischemia, myocardial infarction, congestive heart failure, dilated and hypertrophic cardiomyopathy, cardiac arrhythmia, cardiac hypertrophy, cardiac transplantation and rejection. For example, if the cardiac condition, such as ischemia, can be treated or improved by inducing angiogenesis, then the rAAV vector used in accordance with the method of this invention would encode an angiogenesis factor.

Thus the rAAV vector is infused into a coronary artery for a time and in an amount sufficient to stably and efficiently transduce cardiac tissue perfused by the artery, wherein the AAV vector encodes a therapeutically-effective molecule which is expressed in the cardiac tissue in an amount effective to treat or ameliorate a cardiovascular condition including, but not limited to, inducing angiogenesis, inhibiting angiogenesis, stimulating or inhibiting cell proliferation, treating restenosis, treating atherosclerosis, treating congestive heart failure, treating ischemic cardiomyopathies or treating malignant

arrhythmias, myocardial infarction, congestive heart failure, or dilated and hypertrophic cardiomyopathy.

The method of the present invention can be used with any animal, including but not limited to, mammals such as rodents, dogs, cats, cattle, primates and humans.

5 Preferably the method is used for gene therapy to treat human acquired or inherited cardiac conditions or diseases.

The present invention thus provides a method of treating and/or ameliorating a cardiovascular condition by infusing an rAAV vector for a time and in an amount sufficient to stably and efficiently transduce cardiomyocytes which was heretofore unachievable by methods known in the art. For this invention, stable and efficient transduction means that significant number of cardiomyocytes are transduced and are capable of expressing the protein for a prolonged period of time. Stable and efficient transduction occurs over a period of time and can actually be observed over time as an increase in the percentage of transduced cardiomyocytes, as continued expression of the transgene, or as continued observation of the therapeutic effect at a molecular, microscopic or macroscopic level. For example, with angiogenesis, stable and efficient transduction can be manifested by ongoing development and/or growth of new blood vessels, by observing the improved blood flow to the heart, or by determining/measuring the level of ischemia in the heart tissue.

20 Alternatively, efficient transduction occurs when at least about 10%, and preferably more, of the cardiomyocytes have been transduced, i.e., infected by, the rAAV. By following the methods of the invention and by observing at particular times after transduction ranging over a few to many weeks, about 25%, about 40% or even about 50% of the cardiomyocytes will be transduced. While about 10% of the cardiomyocytes can be transduced using only rAAV, this percentage can be increased by co-infusing adenovirus as a helper virus without adverse effects.

25 The time of infusion contributes to achieving stable and efficient transduction of the cardiomyocytes as well. Thus the infusion time ranges from about 2 minutes to about 30 minutes, more preferably from about 5 minutes to about 20 minutes and most preferably is about fifteen minutes.

The amount of rAAV infused into the animal is proportional to the body weight of the animal. Hence in accordance with the invention, stable and efficient transduction occurs when the amount of rAAV infused ranges from about 1×10^5 IU (infectious units) of AAV per gram body weight to about 1×10^9 IU AAV per gram body weight, and preferably from about 1×10^6 IU AAV per gram body weight to about 1×10^8 IU AAV per gram body weight, and most preferably is about $5-6 \times 10^7$ IU AAV per gram body weight.

5 The example described below demonstrates efficient and stable transduction of cardiac myocytes *in vivo* after intracoronary infusion of an rAAV vector.

10 Throughout this application, various publications, patents, and patent applications have been referred to. The teachings and disclosures of these publications, patents, and patent applications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which the present invention pertains.

15 It is to be understood and expected that variations in the principles of invention herein disclosed in an exemplary embodiment may be made by one skilled in the art and it is intended that such modifications, changes, and substitutions are to be included within the scope of the present invention.

EXAMPLE

Intracoronary Infusion of rAAV

I. Methods:

5 Plasmids and Viruses

The structure of pAAV_{CMV-LacZ} is shown in Figure 1. Ad_{CMV-LacZ} and the E3-deleted adenovirus, Ad_{d1309}, were propagated and purified as described (Barr 1994).

Propagation and Purification of rAAV

10 rAAV was prepared as described (Rolling et al. (1995) *Mol. Biotechnol.* 3:9-15) and purified by cesium chloride gradient centrifugation. Viral titer was assessed by a dot blot hybridization assay to determine the number of viral genomes per milliliter and by infecting HeLa cells with the virus and staining with X-gal 24 hours after infection. All viral preparations had titers of 1 to 2×10^{11} genomes/mL, and 2 to 3×10^9 infectious units (IU)/mL.

15 Intracoronary Perfusion With rAAV

Adult C57BL/6 mouse hearts were perfused via the left carotid artery with cardioplegia solution (110 mmol/L NaCl, 25 mmol/L KCl, 22 mmol/L NaHCO₃, 16 mmol/L MgCl₂, 0.8 mmol/L CaCl₂, 40 mmol/L glucose) at 4°C until they stopped beating. They were then perfused ex vivo for 15 minutes with 1.5×10^9 IU of AAV_{CMV-LacZ} in 0.5 mL of PBS at a rate of 33 μL/min at 4°C. After perfusion, the hearts were transplanted into the neck of a syngeneic host with anastomosis of the donor aorta to the right common carotid artery of the host and anastomosis of the donor pulmonary artery to the right external jugular vein (Lin et al. (1990b) *J. Heart Transplant.* 9:720-723) (n=3 for each time point).

25 X-Gal Staining

Freshly isolated hearts were fixed in PBS plus 1.25% glutaraldehyde for 10 minutes at room temperature, stained overnight with X-gal (Lin 1990a), and counterstained with eosin.

30

β-Galactosidase Activity

Cardiac homogenates were assayed for β -galactosidase (β -gal) activity and protein concentrations. β -Gal activities were normalized for total protein and for the number of infectious rAAV or RDAd particles injected.

5

II. Results

Many clinical applications of myocardial gene therapy may require the stable and efficient transduction of cardiomyocytes distributed throughout large areas of myocardium. Coronary artery infusions of RDAd have been shown to result in the efficient transduction of cardiomyocytes throughout the region of perfused myocardium (Barr 1994). To test whether rAAV is similarly capable of transducing cardiomyocytes after coronary artery perfusion, hearts from C57BL/6 mice were explanted and perfused with 1.5×10^9 IU of AAV_{CMV-LacZ} for 15 minutes at 4°C via a catheter placed in the left common carotid artery. These perfused hearts were then transplanted into syngeneic hosts, and the arterial circulation was reestablished by anastomosis of the transplanted aorta to the recipient carotid artery. Such transplanted and revascularized hearts resumed beating and continued to do so until the recipient mice were killed 2, 4, or 8 weeks after perfusion. Two weeks after perfusion, small numbers (<1 %) of β -gal-positive cardiomyocytes were detected throughout the myocardium of the rAAV-perfused hearts (Figure 2). By 4 weeks after perfusion, \approx 40% of the cardiomyocytes were β -gal positive. This high level of transduction was stable at weeks after perfusion, with >50% of the cardiomyocytes continuing to express β -gal. Similar increases in recombinant gene expression over the first several weeks after rAAV infection have been observed in skeletal muscle (Fisher 1997; Kessler 1998). It has been postulated that such increases may reflect the gradual process of conversion of the single-stranded AAV genome into a double-stranded DNA molecule that is competent for transcription of the transgene (Ferrari et al. (1996) *J. Virol.* 70:3227-3234). Thus, rAAV delivered by coronary artery perfusion can be used to stably transduce cardiomyocytes throughout the myocardium.

WE CLAIM:

1. A method of treating a cardiovascular condition which comprises:
 - infusing a recombinant adeno-associated virus (AAV) vector into a coronary artery or a coronary sinus for a time and in an amount sufficient to stably and efficiently transduce cardiomyocytes perfused by said artery or said sinus, wherein said AAV vector encodes at least one nucleic acid operably linked to a control region, said nucleic acid encoding a therapeutically-effective molecule; and
 - expressing said therapeutically-effective molecule in an amount effective to treat or ameliorate said cardiovascular condition.
- 10 2. The method of Claim 1, wherein said AAV transduces at least about 10 % of said cardiomyocytes.
3. The method of Claim 1, wherein said AAV transduces at least about 40% of said cardiomyocytes.
- 15 4. The method of Claim 1, wherein said AAV transduces at least about 50% of said cardiomyocytes.
5. The method of Claim 1, wherein said AAV is infused for at least about 2 minutes to about 30 minutes.
- 20 6. The method of Claim 1, wherein said AAV is infused for at least about 5 minutes to about 20 minutes.
7. The method of Claim 1, wherein said AAV is infused for about 15 minutes.
8. The method of Claim 1, wherein said amount of AAV is about 1×10^5 IU AAV per gram body weight to about 1×10^9 IU AAV per gram body weight.
- 25 9. The method of Claim 9, wherein said amount of AAV is about 1×10^6 IU AAV per gram body weight to about 1×10^8 IU AAV per gram body weight.
10. The method of Claim 9, wherein said amount of AAV is about 6×10^7 IU AAV per gram body weight.
- 30 11. The method of Claim 1, wherein about 1×10^5 IU AAV per gram body weight to about 1×10^9 IU AAV per gram body weight is infused for about 2 to about 30 minutes.
12. The method of Claim 11, wherein about 1×10^6 IU AAV per gram body weight to about 1×10^8 IU AAV per gram body weight is infused.

13. The method of Claim 11, wherein about 6×10^7 IU AAV per gram body weight is infused.

14. The method of any one of Claims 11, 12 or 13, wherein said AAV is infused for about 5 to about 20 minutes.

5 15. The method of any one of Claims 11, 12 or 13, wherein said AAV is infused for about 15 minutes.

16. The method of Claim 11, wherein about 6×10^7 IU AAV per gram body weight is infused for about 15 minutes.

10 17. The method of Claim 1, wherein said coronary artery is infused *ex vivo or in vivo.*

18. The method of Claim 1, wherein said therapeutically-effective molecule is an anti-sense RNA or a protein.

15 19. The method of Claim 1 wherein therapeutically-effective molecule is an ion channel gene, a contractile protein, a phospholamban, a β adrenergic receptor, a β adrenergic kinase, a growth factor, an angiogenic factor, a protein or nucleic acid capable of inducing angiogenesis, or a protein or nucleic acid capable of inhibiting angiogenesis.

20 20. The method of Claim 1, wherein said therapeutically-effective molecule is FGF-1, FGF-2, FGF-5, VEGF, or HIF-1.

21. The method of Claim 1, wherein said therapeutically-effective molecule is thymidine kinase, p21, p27, p53, Rb or NF- κ B.

25 22. The method of Claim 1, wherein said cardiovascular condition is restenosis, atherosclerosis, congestive heart failure, ischemic cardiomyopathy, malignant arrhythmia, myocardial infarction, congestive heart failure, or dilated and hypertrophic cardiomyopathy.

23. The method of Claim 1, wherein treating or ameliorating said cardiovascular condition is for inducing angiogenesis, inhibiting angiogenesis, stimulating or inhibiting cell proliferation, treating restenosis, treating atherosclerosis, treating congestive heart failure, treating ischemic cardiomyopathy or treating malignant arrhythmia.

ABSTRACT OF THE DISCLOSURE

This invention relates to the use of recombinant adeno-associated virus (rAAV) vectors to transduce cardiomyocytes *in vivo* by infusing the rAAV into a coronary artery or coronary sinus. rAAV infection is not associated with detectable myocardial inflammation or myocyte necrosis. Thus, rAAV is a useful vector for the stable expression of therapeutic genes in the myocardium and can be used to deliver genes for inducing angiogenesis, inhibiting angiogenesis, stimulating cell proliferation, inhibiting cell proliferation and/or treating or ameliorating other cardiovascular conditions.

5

Fig. 1





Fig. 2

2 weeks



4 weeks



8 weeks

